Rigel Pharmaceuticals, Inc.
TGF- inhibitors
Last updated:
Abstract:
Disclosed are aryl pyrimidine compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, R and R' are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-.beta. superfamily, and can be used to treat disease by blocking such activity. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
29 Mar 2016
Issue date:
1 Jun 2021